Spectral AI Inc

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Spectral AI excels in Q2, eyes FDA approval and revenue growth

Spectral AI's strong Q2 performance, progress in AI technology, and strategic initiatives position them well for future growth. While facing challenges in FDA approval and commercialization, the company's cash position and revenue guidance offer stability and potential. Opportunities for growth through government contracts and capital access further enhance their prospects.

Spectral AI Inc reports robust Q3 results, eyes AI expansion

Spectral AI Inc (MDAI) demonstrated strong financial performance in Q3 2024, with revenue growth, improved margins, and a focus on key study milestones.
The company's strategic partnerships, clear priorities, and upcoming data release position it well for future growth and innovation in the medical AI space.
While facing challenges in regulatory compliance and market expansion, Spectral AI Inc has opportunities to diversify its offerings, enter new markets, and solidify its position as a leader in AI-based medical treatments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spectral AI, Inc. is a predictive artificial intelligence company. It focuses on medical diagnostics for faster and more accurate treatment decisions in wound care for burn, DFU, and future clinical applications. Its DeepView platform is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. The company was founded on November 17, 2020 and is headquartered in Dallas, TX.

Spectral AI Inc (NASDAQ:MDAI) an artificial intelligence company specializing in medical diagnostics for wound care, is set to join the Russell Microcap Index. The Russell Microcap Index is designed to represent the microcap segment of the U.S.

Spectral AI to join Russell Microcap Index

DALLAS, May 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective following the closing of US equity markets on Friday, June 28, 2024 according to a preliminary list of additions posted Friday, May 24, 2024.

Spectral AI Set to Join Russell Microcap® Index

DALLAS, May 28, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Peter M. Carlson, Chief Executive Officer of Spectral AI, is scheduled to participate in a fireside chat at Benzinga's “AI Unleashed: Exploring the Possibilities” virtual event, taking place on May 30, 2024.

Spectral AI to Participate in Benzinga's “AI Unleashed: Exploring the Possibilities” Virtual Event

Spectral AI Inc (NASDAQ:MDAI) announced that several of its officers and directors acquired approximately 113,000 shares of Spectral AI common stock in open market transactions in May.   These transactions were made publicly and not through private arrangements, which can indicate confidence in the company's future prospects by its leadership.

Spectral AI executives acquire shares as company advances AI wound care technology

DALLAS, May 17, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that several of the Company's officers and directors acquired approximately 113,000 shares of Spectral AI common stock in open market transactions on May 10, 2024 and May 15, 2024.

Spectral AI Announces Purchases of Over 100,000 Shares by Insiders

DALLAS, May 15, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2024 Annual Meeting of Stockholders held on May 14, 2024 (the “AGM”). At the AGM, stockholders overwhelmingly approved each of the four proposals set forth by the Company.

Spectral AI Announces Voting Results from 2024 Annual Meeting of Stockholders and the Appointment of Erich Spangenberg to the Board of Directors

Spectral AI, Inc. (NASDAQ:MDAI ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Devin Sullivan - Managing Director, The Equity Group, Inc. Peter Carlson - CEO Vincent Capone - CFO and General Counsel Conference Call Participants Ramakanth Swayampakula - H.C. Wainwright John Vandermosten - Zacks Christopher Recouso - Partner Cap Group Operator Good day, and welcome to the Spectral AI First Quarter 2024 Financial Results Conference Call.

Spectral AI, Inc. (MDAI) Q1 2024 Earnings Call Transcript

Spectral AI Inc (NASDAQ:MDAI) hailed progress in the first quarter towards first commercial product revenue later this year, along with strengthening of the management team and financial position. The developer of the DeepView wound imaging system reported research & development revenue of $6.3 million for Q1, compared to $5.1 million a year ago, as it carried out an increased level of activity under the contracts with the US Biomedical Advanced Research & Development Authority (BARDA).

Spectral AI hails progress towards first sales and pre-FDA clinical trial

Q1 Overview Research & Development Revenue of $6.3 Million Improved Capital Structure Reflected in Cash of $10.2 Million DeepView AI®-Burn Devices Deployed in UK; Expect Commercial Revenue in 2H 2024 Additional Regulatory Submissions in US and UK for DeepView™ System Expected in 2024 and 2025 DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2024 (“Q1 2024”) and provided an update on its ongoing business activities. “During the first quarter we continued to execute against our strategic priorities resulting in significant accomplishments across the enterprise,” said Peter M.

Spectral AI Announces 2024 First Quarter Financial Results

DALLAS, May 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that management is scheduled to present and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Investor Conference, taking place on May 8-9, 2024.

Spectral AI to Participate at the Sidoti Micro-Cap Virtual Investor Conference

Spectral AI Inc (NASDAQ:MDAI) announced it has been awarded the Commitment to Quality Achievement Award from the Texas Manufacturer Assistance Center (TMAC) for its UK Conformity Assessed (UKCA) Mark Attainment. The Dallas-based company is advancing its DeepView technology, a predictive device that allows clinicians to assess a wound and provide faster and more accurate treatment insights.

Spectral AI receives TMAC Quality Achievement Award for wound care technology

DALLAS, April 30, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the company received the Commitment to Quality Achievement Award from the Texas Manufacturer Assistance Center (TMAC) for their UKCA Mark Attainment.

Spectral AI Awarded Quality Achievement Award from the Texas Manufacturer Assistance Center

DALLAS, April 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results.

Spectral AI Schedules 2024 First Quarter Financial Results and Conference Call

Spectral AI Inc (NASDAQ:MDAI) has appointed Erich Spangenberg to lead its health care IP-focused subsidiary, Spectral IP. Spangenberg, Spectral AI's largest shareholder, brings decades of experience in global IP investment and monetization.

Spectral AI appoints Erich Spangenberg as CEO of Spectral IP

Spangenberg brings significant IP monetization experience and the potential to unlock additional value for Spectral AI shareholders Spangenberg brings significant IP monetization experience and the potential to unlock additional value for Spectral AI shareholders

Spectral AI Names Erich Spangenberg CEO of its IP Focused Subsidiary and Explores Potential Spin-Off of that Subsidiary

Experienced Burn Industry Executive Champions Pivot to Commercialization Experienced Burn Industry Executive Champions Pivot to Commercialization

Spectral AI Appoints Jeremiah Sparks as Chief Commercialization Officer

Spectral AI, Inc. (MDAI) Q4 2023 Earnings Call Transcript

Spectral AI Inc (NASDAQ:MDAI) has reiterated its 2024 research and development (R&D) revenue guidance of $28 million which notably does not include expected contributions from the commercialization of its DeepView burn wound care system in the United Kingdom. The predictive AI company focused on medical diagnostics for improved wound care achieved revenue of $18.1 million for 2023, it reported after Wednesday's closing bell.

Spectral AI reiterates 2024 R&D revenue guidance which excludes DeepView commercialization contributions

2023 Research & Development Revenue of $18.1 Million Expected to Increase to $28.0 Million in 2024

Spectral AI Announces 2023 Fourth Quarter and Full Year Financial Results

Spectral AI Inc (NASDAQ:MDAI) announced that it has entered into a fixed-price prepaid advance and standby equity purchase agreement with a longstanding investor. The company said that the total capacity under the agreement is $30 million which consists of a prepaid advance of $12.5 million.

Spectral AI announces up to $30M equity funding agreement with long-time investor

Issuance of Convertible Instrument Balances Certainty, Timing, and Execution Capital Supports Strategic Imperatives and Commercialization Initiatives

Spectral AI Secures Access to $12.5 Million of New Equity Capital

Spectral AI Inc (NASDAQ:MDAI) announced that it has received a $1 million investment from an affiliate of its largest shareholder into its newly created subsidiary Spectral IP.  Spectral IP will be focused on developing intellectual property for the broader AI ecosystem through acquisitions, strategic partnerships, and collaborations with AI technology providers, healthcare institutions, and research organizations.

Spectral AI secures $1M investment in AI IP subsidiary

DALLAS, March 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has received a $1 million investment from an affiliate of its largest shareholder into its recently formed subsidiary Spectral IP, Inc. (“Spectral IP”). The investment is structured as a note payable with a one-year maturity, an interest rate of 8%, and requiring earlier prepayment if Spectral IP is spun off to the Company's shareholders or sold.

Spectral AI Announces Receipt of $1 Million of Financing for Spectral IP, Inc., its Intellectual Property Subsidiary Focused on the Broader Artificial Intelligence Ecosystem

DALLAS, March 13, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, March 27, 2024 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results.

Spectral AI Schedules 2023 Fourth Quarter and Full Year Financial Results and Conference Call

Spectral AI (NASDAQ: MDAI ) stock is on the rise Tuesday after the artificial intelligence ( AI ) company announced a $500,000 government contract for its wound imaging technology. According to a press release from Spectral AI, it's teaming up with the Defense Health Agency (DHA) and the US Army Medical Material Development Activity (USAMMDA).

News for Spectral AI Inc Stock (MDAI)